Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) Enterprise Value (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Enterprise Value for 7 consecutive years, with -$197.5 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 18.04% to -$197.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$197.5 million through Dec 2025, up 18.04% year-over-year, with the annual reading at -$197.5 million for FY2025, 18.04% up from the prior year.
  • Enterprise Value for Q4 2025 was -$197.5 million at Fulcrum Therapeutics, up from -$200.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$25.6 million in Q4 2023, with the low at -$241.0 million in Q4 2024.
  • Average Enterprise Value over 5 years is -$75.3 million, with a median of -$42.4 million recorded in 2025.
  • The sharpest move saw Enterprise Value soared 66.93% in 2022, then plummeted 842.85% in 2024.
  • Over 5 years, Enterprise Value stood at -$35.4 million in 2021, then increased by 0.89% to -$35.1 million in 2022, then increased by 27.17% to -$25.6 million in 2023, then tumbled by 842.85% to -$241.0 million in 2024, then increased by 18.04% to -$197.5 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$197.5 million, -$200.6 million, and -$42.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.